Gius D R, Ezhevsky S A, Becker-Hapak M, Nagahara H, Wei M C, Dowdy S F
Howard Hughes Medical Institute and Department of Pathology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Cancer Res. 1999 Jun 1;59(11):2577-80.
Progression of cells through the G1 phase of the cell cycle requires cyclin D:Cdk4/6 and cyclin E:Cdk2 complexes; however, the duration and ordering of these complexes remain unclear. To address this, we synthesized a peptidyl mimetic of the Cdk4/6 inhibitor, p16INK4a that contained an NH2-terminal TAT protein transduction domain. Transduction of TAT-p16 wild-type peptides into cells resulted in the loss of active, hypophosphorylated pRb and elicited an early G1 cell cycle arrest, provided cyclin E:Cdk2 complexes were inactive. We conclude that cyclin D:Cdk4/6 activity is required for early G1 phase cell cycle progression up to, but not beyond, activation of cyclin E:Cdk2 complexes at the restriction point and is thus nonredundant with cyclin E:Cdk2 in late G1.
细胞通过细胞周期G1期的进程需要细胞周期蛋白D:细胞周期蛋白依赖性激酶4/6(Cdk4/6)和细胞周期蛋白E:细胞周期蛋白依赖性激酶2(Cdk2)复合物;然而,这些复合物的持续时间和顺序仍不清楚。为了解决这个问题,我们合成了一种Cdk4/6抑制剂p16INK4a的肽模拟物,其含有一个NH2末端TAT蛋白转导结构域。将TAT-p16野生型肽转导到细胞中导致活性、低磷酸化的视网膜母细胞瘤蛋白(pRb)丢失,并引发早期G1期细胞周期停滞,前提是细胞周期蛋白E:Cdk2复合物无活性。我们得出结论,在限制点处,细胞周期蛋白D:Cdk4/6活性是早期G1期细胞周期进程直至但不超过细胞周期蛋白E:Cdk2复合物激活所必需的,因此在G1晚期与细胞周期蛋白E:Cdk2不存在冗余。